JP2020523367A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523367A5 JP2020523367A5 JP2019568760A JP2019568760A JP2020523367A5 JP 2020523367 A5 JP2020523367 A5 JP 2020523367A5 JP 2019568760 A JP2019568760 A JP 2019568760A JP 2019568760 A JP2019568760 A JP 2019568760A JP 2020523367 A5 JP2020523367 A5 JP 2020523367A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- carboxamide
- substituted
- naphthylidine
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 108
- 125000001153 fluoro group Chemical group F* 0.000 claims 57
- -1 chloro, bromo, iodo Chemical group 0.000 claims 43
- 125000001424 substituent group Chemical group 0.000 claims 34
- 208000029549 Muscle injury Diseases 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 23
- 239000001257 hydrogen Substances 0.000 claims 23
- 125000004043 oxo group Chemical group O=* 0.000 claims 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims 18
- 125000003545 alkoxy group Chemical group 0.000 claims 17
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims 14
- 125000002393 azetidinyl group Chemical group 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 11
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- SBUKLPSBNFWJCU-UHFFFAOYSA-N ClIBr Chemical compound ClIBr SBUKLPSBNFWJCU-UHFFFAOYSA-N 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 8
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 210000003205 muscle Anatomy 0.000 claims 6
- 201000006938 muscular dystrophy Diseases 0.000 claims 6
- 125000002971 oxazolyl group Chemical group 0.000 claims 6
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 5
- 210000003979 eosinophil Anatomy 0.000 claims 5
- 125000005842 heteroatom Chemical group 0.000 claims 5
- 208000014674 injury Diseases 0.000 claims 5
- 150000003857 carboxamides Chemical class 0.000 claims 4
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 210000002435 tendon Anatomy 0.000 claims 3
- 230000001256 tonic effect Effects 0.000 claims 3
- 230000008736 traumatic injury Effects 0.000 claims 3
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 208000034656 Contusions Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 claims 2
- 101710082112 Hematopoietic prostaglandin D synthase Proteins 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 210000001264 anterior cruciate ligament Anatomy 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 230000009519 contusion Effects 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- KLDGHPMEPAPPFX-UHFFFAOYSA-N pyrido[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=CN=CC2=CC(C(=O)N)=CN=C21 KLDGHPMEPAPPFX-UHFFFAOYSA-N 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 230000003252 repetitive effect Effects 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000033309 Analgesic asthma syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000004262 Food Hypersensitivity Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010018691 Granuloma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000034693 Laceration Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010028331 Muscle rupture Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims 1
- HEWVQMIXEMUPRL-HDJSIYSDSA-N OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C1=CC2=C(N=C(N=C2)OC)N=C1 Chemical compound OC(C)(C)[C@@H]1CC[C@H](CC1)NC(=O)C1=CC2=C(N=C(N=C2)OC)N=C1 HEWVQMIXEMUPRL-HDJSIYSDSA-N 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010049422 Precancerous skin lesion Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039203 Road traffic accident Diseases 0.000 claims 1
- 206010052568 Urticaria chronic Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000024376 chronic urticaria Diseases 0.000 claims 1
- 206010010121 compartment syndrome Diseases 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 125000006317 cyclopropyl amino group Chemical group 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 210000003414 extremity Anatomy 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 235000020932 food allergy Nutrition 0.000 claims 1
- 210000004394 hip joint Anatomy 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000004968 inflammatory condition Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000013150 knee replacement Methods 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000013465 muscle pain Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- ONLRKTIYOMZEJM-UHFFFAOYSA-N n-methylmethanamine oxide Chemical compound C[NH+](C)[O-] ONLRKTIYOMZEJM-UHFFFAOYSA-N 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 230000000399 orthopedic effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000036544 posture Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000001932 seasonal effect Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 230000001360 synchronised effect Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000001319 vasomotor rhinitis Diseases 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762518779P | 2017-06-13 | 2017-06-13 | |
| US62/518,779 | 2017-06-13 | ||
| US201762522869P | 2017-06-21 | 2017-06-21 | |
| US62/522,869 | 2017-06-21 | ||
| PCT/IB2018/054206 WO2018229629A1 (en) | 2017-06-13 | 2018-06-11 | Chemical compounds as h-pgds inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020523367A JP2020523367A (ja) | 2020-08-06 |
| JP2020523367A5 true JP2020523367A5 (enExample) | 2021-06-10 |
Family
ID=62948277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568760A Ceased JP2020523367A (ja) | 2017-06-13 | 2018-06-11 | Ｈ−ｐｇｄｓ阻害剤としての化学化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11149035B2 (enExample) |
| EP (1) | EP3638672A1 (enExample) |
| JP (1) | JP2020523367A (enExample) |
| CN (1) | CN110753692A (enExample) |
| BR (1) | BR112019026452A2 (enExample) |
| CA (1) | CA3066979A1 (enExample) |
| TW (1) | TW201908311A (enExample) |
| UY (1) | UY37764A (enExample) |
| WO (1) | WO2018229629A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111479814A (zh) * | 2017-12-13 | 2020-07-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的稠合的吡啶 |
| JP2022506850A (ja) * | 2018-11-08 | 2022-01-17 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 化学化合物 |
| CN109651241B (zh) * | 2018-12-27 | 2021-02-09 | 上海毕得医药科技股份有限公司 | 一种4-溴-6-氯烟醛的合成方法 |
| US20230339937A1 (en) | 2020-06-19 | 2023-10-26 | Sato Pharmaceutical Co., Ltd. | Condensed ring compounds that inhibit h-pgds |
| AU2021381949A1 (en) | 2020-11-18 | 2023-06-15 | Deciphera Pharmaceuticals, Llc | Gcn2 and perk kinase inhibitors and methods of use thereof |
| CN112430632B (zh) * | 2020-11-18 | 2022-09-13 | 上海合全药物研发有限公司 | 2-((反式)-4-氨基环己烷基)异丙醇的制备方法 |
| US20250074906A1 (en) | 2021-12-17 | 2025-03-06 | Sato Pharmaceutical Co., Ltd. | Azaindole derivative that inhibits h-pgds |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2376024A1 (en) | 1999-06-02 | 2000-12-07 | Nps Pharmaceuticals, Inc. | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| EP1389209B1 (en) | 2001-04-24 | 2009-04-08 | Purdue Research Foundation | Folate mimetics and folate-receptor binding conjugates thereof |
| US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
| US8163769B2 (en) | 2002-03-12 | 2012-04-24 | Abbott Laboratories | Antibacterial compounds |
| EP1539163A1 (en) | 2002-08-13 | 2005-06-15 | Warner-Lambert Company LLC | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
| WO2004056744A1 (en) | 2002-12-23 | 2004-07-08 | Janssen Pharmaceutica N.V. | Adamantyl acetamides as hydroxysteroid dehydrogenase inhibitors |
| WO2005035526A1 (en) | 2003-10-09 | 2005-04-21 | Argenta Discovery Ltd. | Bicyclic compounds and their therapeutic use |
| WO2005094805A1 (ja) | 2004-04-01 | 2005-10-13 | Institute Of Medicinal Molecular Design. Inc. | イミン誘導体及びアミド誘導体 |
| TW200720255A (en) | 2005-07-13 | 2007-06-01 | Taiho Pharmaceutical Co Ltd | Benzoimidazole compound capable of inhibiting prostaglandin d synthetase |
| JP2007051121A (ja) | 2005-07-22 | 2007-03-01 | Taiho Yakuhin Kogyo Kk | プロスタグランジンｄ合成酵素を阻害するピリミジン化合物 |
| DOP2006000210A (es) | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| JP2010513458A (ja) | 2006-12-19 | 2010-04-30 | ファイザー・プロダクツ・インク | Ｈ−ｐｇｄｓの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンｄ２の仲介による疾患を治療するためのその使用 |
| BRPI0809974A2 (pt) | 2007-03-30 | 2014-10-07 | Sanofi Aventis | Compostos de pirimidina hidrazida como inibidores de pgds |
| GB0706793D0 (en) | 2007-04-05 | 2007-05-16 | Evotec Ag | Compounds |
| US9603848B2 (en) | 2007-06-08 | 2017-03-28 | Senomyx, Inc. | Modulation of chemosensory receptors and ligands associated therewith |
| TW201010997A (en) * | 2008-06-18 | 2010-03-16 | Pfizer Ltd | Nicotinamide derivatives |
| CA2725481A1 (en) * | 2008-06-18 | 2009-12-23 | Pfizer Limited | Nicotinamide derivatives |
| WO2010033977A2 (en) | 2008-09-22 | 2010-03-25 | Cayman Chemical Company | Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases |
| MX2011009423A (es) | 2009-03-09 | 2011-09-28 | Taiho Pharmaceutical Co Ltd | Compuesto de piperazina capaz de inhibir prostaglandina d sintasa. |
| JP2011042643A (ja) | 2009-07-24 | 2011-03-03 | Bayer Cropscience Ag | 殺虫性カルボキサミド類 |
| EP2487175A1 (en) * | 2009-10-06 | 2012-08-15 | Kyowa Hakko Kirin Co., Ltd. | Pharmaceutical product containing aromatic heterocyclic compound |
| BR112012007635B1 (pt) | 2009-10-08 | 2019-07-09 | Sanofi | Compostos derivados de feniloxadiazol como inibidores de pgds, composição farmacêutica compreendendo os mesmos e seus processos de preparação |
| MY161134A (en) * | 2010-01-22 | 2017-04-14 | Taiho Pharmaceutical Co Ltd | Piperazine compound having a pgds inhibitory effect |
| GB201007347D0 (en) | 2010-04-30 | 2010-06-16 | Karus Therapeutics Ltd | Compounds |
| WO2012087872A1 (en) | 2010-12-23 | 2012-06-28 | Merck Sharp & Dohme Corp. | Quinolines and aza-quinolines as crth2 receptor modulators |
| US20130072473A1 (en) | 2011-05-09 | 2013-03-21 | Proteostasis Therapeutics, Inc. | Compounds for treating protein folding disorders |
| HK1203412A1 (en) | 2011-12-28 | 2015-10-30 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| WO2013134298A1 (en) | 2012-03-07 | 2013-09-12 | Deciphera Pharmaceuticals, Llc | Raf inhibitor compounds |
| EP2877166B1 (en) | 2012-07-27 | 2018-02-28 | Biogen MA Inc. | 1-[7-(cis-4-methyl-cyclohexyloxy)-8-trifluoromethyl-naphthalen-2-ylmethyl]-piperidine-4-carboxylic acid derivatives as autotaxin (ATX) modulators for treating inflammations and autoimmune disorders |
| JP6324380B2 (ja) | 2012-07-27 | 2018-05-16 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | Ｓ１ｐ調節剤および／またはａｔｘ調節剤である化合物 |
| WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
| BR112016013018A2 (pt) | 2013-12-09 | 2017-08-08 | Ucb Biopharma Sprl | Derivados heteroaromáticos bicíclicos fundidos como moduladores de atividade de tnf |
| JP2017522324A (ja) | 2014-07-17 | 2017-08-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 新規ナフチリジン及びイソキノリンならびにｃｄｋ８／１９阻害剤としてのその使用 |
| BR112017015760A2 (pt) | 2015-01-23 | 2018-03-27 | Gvk Biosciences Private Limited | inibidores de quinase trka |
| CA3008358A1 (en) | 2015-12-17 | 2017-06-22 | Astex Therapeutics Limited | Quinoline-3-carboxamides as h-pgds inhibitors |
| WO2017146128A1 (ja) | 2016-02-26 | 2017-08-31 | 大日本住友製薬株式会社 | イミダゾリルアミド誘導体 |
| JOP20190072A1 (ar) * | 2016-10-13 | 2019-04-07 | Glaxosmithkline Ip Dev Ltd | مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم |
| CN111479814A (zh) * | 2017-12-13 | 2020-07-31 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为h-pgds抑制剂的稠合的吡啶 |
-
2018
- 2018-06-11 EP EP18742598.8A patent/EP3638672A1/en not_active Withdrawn
- 2018-06-11 BR BR112019026452-3A patent/BR112019026452A2/pt not_active Application Discontinuation
- 2018-06-11 WO PCT/IB2018/054206 patent/WO2018229629A1/en not_active Ceased
- 2018-06-11 CA CA3066979A patent/CA3066979A1/en not_active Abandoned
- 2018-06-11 US US16/621,927 patent/US11149035B2/en not_active Expired - Fee Related
- 2018-06-11 CN CN201880039565.7A patent/CN110753692A/zh active Pending
- 2018-06-11 TW TW107119972A patent/TW201908311A/zh unknown
- 2018-06-11 JP JP2019568760A patent/JP2020523367A/ja not_active Ceased
- 2018-06-11 UY UY0001037764A patent/UY37764A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523367A5 (enExample) | ||
| JP2019502691A5 (enExample) | ||
| ES2277149T3 (es) | Derivados de piridina como moduladores de los receptores cb2. | |
| RU2003105885A (ru) | Ингибиторы клеточной адгезии, опосредованной альфа 4-интегринами | |
| RU2017145650A (ru) | Ингибиторы тирозинкиназы брутона | |
| HUP0200124A2 (en) | Phenyl- and pyridinyl derivatives, process for their preparation and pharmaceutical compositions containing them | |
| JP2005538099A5 (enExample) | ||
| EA039482B1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
| KR102426921B1 (ko) | 헤테로아릴아미도피리딘올 유도체 및 이를 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 약학적 조성물 | |
| JP2008528542A5 (enExample) | ||
| Jung et al. | Brace compression for treatment of pectus carinatum | |
| JP2018522861A5 (enExample) | ||
| ZA202201828B (en) | Therapeutic fusion proteins | |
| RU2013130022A (ru) | Новые бензиловые производные азетидина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| JP2020502213A5 (enExample) | ||
| HUP0201315A2 (hu) | 4-Fenil-pirimidin-származékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyászati készítmények | |
| JP2010509233A5 (enExample) | ||
| JP2005500354A5 (enExample) | ||
| WO2005080342A1 (en) | Pyridine derivatives and their use as cb2 receptor modulators | |
| JP2007506726A5 (enExample) | ||
| WO2021023207A1 (zh) | Jak激酶抑制剂及其用途 | |
| RU2013130023A (ru) | Новые производные пиридина в качестве модуляторов рецептора сфингозин 1-фосфата (s1p) | |
| Zheng et al. | Distal radius T-plate for 18 patients with vertical shear medial malleolus fractures | |
| Song et al. | Changes in anatomical parameters of the hip following femoral head necrosis and hip replacement: A 10-year follow-up survery | |
| Sabat et al. | Medial dislocation of elbow associated with a fracture of the lateral humeral condyle in a child with pre-existing cubitus varus |